AKESO INC. O.N. - Asset Resilience Ratio
AKESO INC. O.N. (4RY) has an Asset Resilience Ratio of 2.18% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Also explore AKESO INC. O.N. asset portfolio for the complete picture of this company's asset base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2025)
This chart shows how AKESO INC. O.N.'s Asset Resilience Ratio has changed over time. See AKESO INC. O.N. (4RY) net asset quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down AKESO INC. O.N.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 4RY market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €349.21 Million | 2.18% |
| Total Liquid Assets | €349.21 Million | 2.18% |
Asset Resilience Insights
- Limited Liquidity: AKESO INC. O.N. maintains only 2.18% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
AKESO INC. O.N. Industry Peers by Asset Resilience Ratio
Compare AKESO INC. O.N.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.11% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
|
Hyundai Bioscience Co. Ltd
KQ:048410 |
Biotechnology | 13.57% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 82.25% |
|
Lifecome Biochemistry Co Ltd
SHE:002868 |
Biotechnology | 4.69% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
Annual Asset Resilience Ratio for AKESO INC. O.N. (2022–2025)
The table below shows the annual Asset Resilience Ratio data for AKESO INC. O.N..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 2.18% | €349.21 Million ≈ $408.27 Million |
€16.00 Billion ≈ $18.71 Billion |
-1.16pp |
| 2024-12-31 | 3.34% | €425.79 Million ≈ $497.79 Million |
€12.75 Billion ≈ $14.91 Billion |
-5.95pp |
| 2023-12-31 | 9.28% | €852.43 Million ≈ $996.58 Million |
€9.18 Billion ≈ $10.73 Billion |
+5.72pp |
| 2022-12-31 | 3.56% | €195.91 Million ≈ $229.04 Million |
€5.50 Billion ≈ $6.43 Billion |
-- |
About AKESO INC. O.N.
Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer, lung cancer, and liver cancer; and AK112, a PD-1/VEGF bi-specific antibody to treat lung cancer, biliary tract cancer, head and neck squamous cell car… Read more